Foam Attributes

Foam Attributes

Foam  Attributes

FABIOR Foam is an ethanol-free, easy-to-apply foam1,2

The FABIOR Foam Dispenser

FABIOR Foam contains VersaFoam®-AF

  • Spreadable, aqueous-based formulation3
  • Contains light mineral oil, which is an emollient that is considered noncomedogenic3
  • Can be applied to skin of the face and upper trunk
    • Easy to apply to hair-bearing and non–hair-bearing areas
    • Absorbs quickly with no residue or greasiness
  • Penetrates the skin barrier to deliver the molecule into the epidermis and dermis2

FABIOR Foam does NOT contain:

  • Ethanol
  • Fragrance
  • Propylene glycol
  • Parabens

The contribution to efficacy of individual components has not been established.

Although the exact mode of action of tazarotene in acne is not defined, current evidence suggests the basis for the therapeutic effect of FABIOR Foam may be due to:

  • Anti-hyperproliferation
  • Normalizing-of-differentiation
  • Anti-inflammation

The clinical significance of these effects is unknown.

References: 1. FABIOR Foam [package insert]. Greenville, NC: Mayne Pharma; 2016. 2. Weiss S, Wyres M, Brundage T. A novel foam vehicle is consistently preferred by patients for dermatologic conditions. J Am Acad Dermatol. 2011;64(2):AB50. 3. Data on file. Greenville, NC; Mayne Pharma LLC.


FABIOR Foam is a retinoid indicated for the topical treatment of acne vulgaris in patients 12 years of age or older.

For more information, please see full Prescribing Information and Patient Information Leaflet

Important Safety Information

  • FABIOR Foam is contraindicated in pregnancy. FABIOR Foam may cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, treatment should be discontinued and the patient apprised of the potential hazard to the fetus. Females of child-bearing potential should be warned of the potential risk and use of adequate birth-control measures when tazarotene foam is used. The possibility of pregnancy should be considered in females of child-bearing potential at the time of institution of therapy.
  • FABIOR Foam should be used with caution in patients with history of local tolerability reactions or local hypersensitivity.
  • The propellant in FABIOR Foam is flammable. Instruct the patient to avoid fire, flame, and/or smoking during and immediately following application.
  • Because of heightened burning susceptibility, exposure to sunlight (including sunlamps) should be avoided when using FABIOR Foam. Patients must be warned to use sunscreens and protective clothing. Patients with sunburn should be advised not to use FABIOR Foam until fully recovered. Patients who may have considerable sun exposure due to their occupation and those patients with inherent sensitivity to sunlight should exercise particular caution. FABIOR Foam should be used with caution in patients with a personal or family history of skin cancer or if the patient is also taking drugs known to be photosensitizers.
  • FABIOR Foam may cause skin redness, peeling, burning, or excessive pruritus. Concomitant topical acne therapy should be used with caution because a cumulative irritant effect may occur. If skin irritation occurs, therapy with FABIOR Foam should be reduced to an interval the patient can tolerate, temporarily interrupted, or discontinued. In addition, dermatologic medications and cosmetics that have a strong drying effect should be avoided
  • Retinoids should not be used on abraded or eczematous skin, as they may cause severe irritation. Contact with the mouth, eyes, and mucous membranes should be avoided. Weather extremes, such as wind or cold, may be more irritating to patients using FABIOR Foam. Excessive topical application of FABIOR Foam may lead to marked redness, peeling, or discomfort.

Medical Information & Adverse Drug Events Reporting

To report a suspected adverse reaction from one of our products, please contact Mayne Pharma at 1-844-825-8500 or the FDA at 1-800-FDA-1088 or